CNBC's Leanne Miller contributed to this report Clarification: This story has been updated to clarify Scott Brunner's comments.
Its intended for adults with obesity, or those who are overweight with a related condition, even if they dont have diabetes
These Wegovy injection sites are recommended because of their fatty layer that ensures readily absorption of the weight loss drug into the bloodstream
Potential benefit - A patient whose biomarkers suggest rapid metabolism of GLP-1 drugs might be offered a longer-acting formulation, while someone with strong GIP responsiveness could start on a dual-agonist right away, avoiding months of trial-and-error
What Studies Show Early research suggests that CagriSema may help patients lose even more weight than semaglutide alone
The phase 3 TRIUMPH-4 trial extended to 68 weeks and showed continued weight loss throughout, suggesting that longer maintenance periods produce better outcomes